Comparing effects of a long acting GLP-1 receptor agonist liraglutide with a short acting GLP-1 receptor agonist lixisenatide on diabetic cardiac autonomic neuropathy and glycemic variability evaluated by power spectral analysis of 24-hr heart rate and continuous glucose monitoring.

Comparing effects of a long acting GLP-1 receptor agonist liraglutide with a short acting GLP-1 receptor agonist lixisenatide on diabetic cardiac autonomic neuropathy and glycemic variability evaluated by power spectral analysis of 24-hr heart rate and continuous glucose monitoring. - Effects of long and short acting GLP-1 agonists on diabetic cardiovascular neuropathy and glycemic fluctuations. ELABORATE

Status

Recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000017144

Enrollment

Registered

2015-05-01

Start date

2015-05-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

Liraglutide group Lixisenatide group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: 1)Type 2 diabetes who have inadequate glycemic control(HbA1c between 7.0 and 12.4 %) under medical treatment by dieting and exercise cure and/or drug treatment. 2)Over 20 years old and less than 80 years old 3)Sex unquestioned 4)Patients with no history of cardiovascular disease 5)No treatment or treatment with stable doses of antihypertensive and antiplatelet agents for at least 3 months prior to randomization. 6)The patient who gives a written informed

Exclusion criteria

Exclusion criteria: 1)Type 1 diabetes 2)Liver dysfunction (hepatic enzymes more than three times the upper limit of normal ranges) 3)A pregnant woman and/or a woman under breast-feeding 4)Impaired kidney function (serum crearinine greater than 1.3 mg/dl in men, 1.2 mg/dl in women) 5)Diabetic proliferative retinopathy 6)The patients who has an anamnesis of hypersensitivity to the ingredient of a trial drug 7)Cigarette smokers

Design outcomes

Primary

Measure	Time frame
Differences in 24-hr glycemic variability using continuous glucose monitoring systems , Differences in 24-hr heart rate variability evaluated by power spectral analysis Differences in 24-hr mean heart rate	—

Secondary

Measure	Time frame
24-hour blood pressure variability Gastric emptying rate by an acetaminophen loading test Orthostatic hypotension by Schellong test Plasma levels of A- and B-type natriuretic peptide (ANP and BNP) Serum 1, 5 anhidroglucitol (1, 5-AG) Safety evaluation	—

Countries

Japan

Contacts

Public ContactTakanori Tomotsune

Dokkyo Medical University Department of Endocrinology and Metabolism

tomotsu@dokkyomed.ac.jp0282-87-2150

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026